Want to join the conversation?
$CELG 2Q15 Call: Total net product sales grew 22% to approximately $2.25Bil. The growth was driven by strong performances by REVLIMID and POMALYST/IMNOVID. ABRAXANE continues to grow nicely in pancreatic cancer & OTEZLA’s launch remains on track, achieving the desired pre-biologic positioning, strong adoption & is well positioned for future success
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!